By now, most of us have seen the viral video that caught the attention of the tech world: Apple’s Philips product brand officially has dropped one million employees as it ramps up to produce its first batch of new facial-care products.
The company announced the news today on its website.
But the real news isn’t about the layoffs, or about the new-found business acumen of the new employees.
The real news is about the company’s new-generation biotechnology.
The new biotechnology is a new biopharmaceutical that uses an approach similar to that used by the likes of Bristol-Myers Squibb.
The biopharma is designed to grow hair and skin tissue by using an engineered virus that attacks a specific type of DNA in the hair.
The approach has the potential to radically change the way we treat hair and the way our hair and skins are treated, according to the company.
In the video above, a man’s head is surgically shaved with a razor blade to achieve the effect of a facial scalpel.
The video shows the new bioscipt, which looks a lot like the technology used by hair-care brand, L’Oreal, and the new technology is designed so that the hair is grown in a similar fashion to the way that it grows in hair on your head.
The only difference is that the stem cells used for the hair-growth process are engineered to target a different type of cancer cell, rather than a tumor cell, which is what happens when a tumor grows in the scalp.
The idea is to develop a treatment that targets a type of cell that has been shown to be cancerous, instead of the normal hair follicle.
The idea is that if you take a patient’s normal hair, you may be able to remove a tumor and remove the cancer cells, and if you treat a cancer-prone patient with a bioscience treatment, the cancer-free patient would not need to be on chemotherapy.
The company is now working with the U.S. Department of Defense to develop and test the treatment, and in 2019 it will begin clinical trials.
The first clinical trials will be conducted in 2020, and then more trials will begin in 2021, 2022, and finally in 2023.
It will be at least six years before a treatment can be administered to a person, but the company says the technology is “in the very early stages of development.”
There’s another, much more significant step in the process.
The Biotechnology and Biological Sciences Research Council (BBBSRC) will conduct research on the new drug, which has not yet been named.
The agency has not announced a timeline for when it plans to start trials, but it’s expected to begin with a Phase 2 study in 2019, which will involve a clinical trial in 2020 and a Phase 3 trial in 2021.
Once the drug is approved, Phase 3 trials will continue, which should eventually lead to the FDA granting approval for the drug in 2024.
The agency says it will also conduct research into the effectiveness of the treatment and will work with the company to ensure that the treatment is safe and effective.
The Biotechnology Industry Organization (BIO), which represents the companies involved in the development of the biotechnology, has also announced that it will review all biotechnology and biophylactics products and technologies that are proposed for clinical development.
The BIO is expected to report its findings to the Food and Drug Administration by December.
The technology is being developed by the Massachusetts Institute of Technology (MIT) and the Massachusetts General Hospital, which are partners in the Bristol-myers Squab biophage clinical trial.
The Boston-based company is one of the earliest biotech companies to take advantage of the next-generation technology.
The Bristol-MYers SquIBB trial began in the U, S., Canada and Europe in April of this year.
The study was originally scheduled to run for six months, but in May of this 2017, it was extended to a full year, according a statement from the Bristol Research Foundation.MIT is also one of many companies working on an experimental treatment for melanoma, which includes one of those companies.
Bristol- Myers Squabs biophages, which have been around since the 1950s, have been used to treat melanoma in various cancers.
The drug, called AB40, is approved for use in patients with melanoma.
The news of the company downsizing is certainly exciting news for the tech industry, which hasn’t seen the kind of big announcements made by some of the larger companies like Apple and Microsoft.
There are also several companies in the space that have had to go through layoffs, including Twitter, which closed its Silicon Valley offices in 2018.
Apple recently laid off roughly 2,000 employees as the company moves to focus on new products and services.
And the New York Times recently reported that Google and Facebook have had layoffs in recent months as they move to focus their